SLC39A11

Summary

SLC39A11 (solute carrier family 39 member 11, HGNC:14463) is a protein-coding gene on chromosome 17q24.3-q25.1, encoding Zinc transporter ZIP11 (Q8N1S5). Zinc importer that regulates cytosolic zinc concentrations either via zinc influx from the extracellular compartment or efflux from intracellular organelles such as Golgi apparatus.

Predicted to enable copper ion transmembrane transporter activity and zinc ion transmembrane transporter activity. Predicted to be involved in zinc ion transmembrane transport. Predicted to be located in Golgi apparatus; nucleus; and plasma membrane. Predicted to be active in membrane.

Source: NCBI Gene 201266 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 72 total
• Druggable target: yes
• MANE Select transcript: NM_139177

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14463
Approved symbol	SLC39A11
Name	solute carrier family 39 member 11
Location	17q24.3-q25.1
Locus type	gene with protein product
Status	Approved
Aliases	ZIP11
Ensembl gene	ENSG00000133195
Ensembl biotype	protein_coding
OMIM	616508
Entrez	201266

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 20 protein_coding, 4 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000255559, ENST00000542342, ENST00000578620, ENST00000579018, ENST00000579319, ENST00000579491, ENST00000579732, ENST00000579988, ENST00000580557, ENST00000581005, ENST00000581581, ENST00000582179, ENST00000582769, ENST00000583146, ENST00000583507, ENST00000583715, ENST00000584129, ENST00000909849, ENST00000909850, ENST00000909852, ENST00000909853, ENST00000909854, ENST00000909855, ENST00000909856, ENST00000952468, ENST00000952469, ENST00000952470

RefSeq mRNA: 5 — MANE Select: NM_139177 NM_001159770, NM_001352691, NM_001352692, NM_001352693, NM_139177

CCDS: CCDS11690, CCDS54160

Canonical transcript exons

ENST00000255559 — 10 exons

Exon	Start	End
ENSE00001012856	72947752	72947875
ENSE00002689467	72645949	72647662
ENSE00002731313	73092611	73092688
ENSE00003490264	73084808	73084846
ENSE00003519818	73088657	73088775
ENSE00003522932	72736650	72736719
ENSE00003652234	72649170	72649268
ENSE00003690951	72648803	72648961
ENSE00003693035	73031556	73031714
ENSE00003784128	72849634	72849804

Expression profiles

Bgee: expression breadth ubiquitous, 239 present calls, max score 93.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.0254 / max 252.8718, expressed in 1762 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
167882	8.3821	1757
167876	0.5660	161
167881	0.0773	29

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bone marrow cell	CL:0002092	93.82	gold quality
ileal mucosa	UBERON:0000331	92.55	gold quality
pancreatic ductal cell	CL:0002079	91.76	gold quality
colonic epithelium	UBERON:0000397	89.08	gold quality
monocyte	CL:0000576	88.87	gold quality
nasal cavity epithelium	UBERON:0005384	88.80	gold quality
rectum	UBERON:0001052	88.61	gold quality
leukocyte	CL:0000738	88.58	gold quality
upper arm skin	UBERON:0004263	88.37	gold quality
liver	UBERON:0002107	87.71	gold quality
right lobe of liver	UBERON:0001114	87.51	gold quality
duodenum	UBERON:0002114	87.23	gold quality
islet of Langerhans	UBERON:0000006	87.00	gold quality
corpus callosum	UBERON:0002336	86.95	gold quality
left lobe of thyroid gland	UBERON:0001120	86.72	gold quality
bone marrow	UBERON:0002371	86.58	gold quality
thyroid gland	UBERON:0002046	86.47	gold quality
mucosa of transverse colon	UBERON:0004991	85.63	gold quality
right lobe of thyroid gland	UBERON:0001119	85.62	gold quality
saliva-secreting gland	UBERON:0001044	85.61	gold quality
pancreas	UBERON:0001264	85.60	gold quality
kidney epithelium	UBERON:0004819	85.50	gold quality
nasal cavity mucosa	UBERON:0001826	85.47	gold quality
body of pancreas	UBERON:0001150	85.10	gold quality
minor salivary gland	UBERON:0001830	85.03	gold quality
tonsil	UBERON:0002372	84.97	gold quality
parotid gland	UBERON:0001831	84.82	gold quality
oviduct epithelium	UBERON:0004804	84.49	gold quality
mucosa of sigmoid colon	UBERON:0004993	84.29	gold quality
stomach	UBERON:0000945	84.26	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	25.84
E-ANND-3	yes	12.76

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MTF1

miRNA regulators (miRDB)

82 targeting SLC39A11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-4516	99.61	67.78	3390

Literature-anchored findings (GeneRIF, showing 6)

• This paper describes the genomic region surrounding the SOX9 gene which includes SLC39A11 (C17orf26). (PMID:11707075)
• Polymorphisms within ZIP11 gene were significantly associated with bladder cancer risk. (PMID:25900876)
• In glioma tumors, low ZIP11 expression was significantly associated with higher grade. Higher ZIP11 expression was weakly correlated with IDH1 mutation status. (PMID:25921144)
• We found 8 different single nucleotide polymorphisms (SNPs) that are significantly different between subjects without gastritis and those with gastritis… In conclusion, we found that zinc transporter gene ZIP11 is associated with chronic gastritis in the Korean population and it may interact with spicy food, which suggests ZIP11 as a therapeutic target for precision nutrition. (PMID:30122198)
• Increased expression of zinc transporter ZIP4, ZIP11, ZnT1, and ZnT6 predicts poor prognosis in pancreatic cancer. (PMID:33631610)
• Single nucleotide polymorphisms and Zn transport by ZIP11 shape functional phenotypes of HeLa cells. (PMID:38285610)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	SLC39A11	ENSDARG00000098194
mus_musculus	Slc39a11	ENSMUSG00000041654
rattus_norvegicus	Slc39a11	ENSRNOG00000031213
drosophila_melanogaster	Zip48C	FBGN0033665
caenorhabditis_elegans	zipt-11	WBGENE00019077

Protein

Protein identifiers

Zinc transporter ZIP11 — Q8N1S5 (reviewed: Q8N1S5)

Alternative names: Solute carrier family 39 member 11, Zrt- and Irt-like protein 11

All UniProt accessions (11): Q8N1S5, J3KRI1, J3KRX2, J3KS66, J3KT59, J3KTP1, J3QLA9, J3QLB2, J3QQP1, J3QRN3, J3QS49

UniProt curated annotations — full annotation on UniProt →

Function. Zinc importer that regulates cytosolic zinc concentrations either via zinc influx from the extracellular compartment or efflux from intracellular organelles such as Golgi apparatus. May transport copper ions as well. The transport mechanism remains to be elucidated.

Subcellular location. Cell membrane. Nucleus. Cytoplasm. Golgi apparatus.

Similarity. Belongs to the ZIP transporter (TC 2.A.5) family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N1S5-1	1	yes
Q8N1S5-2	2

RefSeq proteins (5): NP_001153242, NP_001339620, NP_001339621, NP_001339622, NP_631916* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003689	ZIP	Family

Pfam: PF02535

Catalyzed reactions (Rhea), 2 shown:

• Cu(2+)(in) = Cu(2+)(out) (RHEA:28703)
• Zn(2+)(in) = Zn(2+)(out) (RHEA:29351)

UniProt features (11 total): transmembrane region 7, chain 1, sequence conflict 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N1S5-F1	76.64	0.51

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 153 (showing top): GOBP_TRANSITION_METAL_ION_TRANSPORT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_COPPER_ION_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, MARTINEZ_RB1_TARGETS_UP, AACTTT_UNKNOWN, RYTTCCTG_ETS2_B, ELK1_01, GOBP_IMPORT_INTO_CELL, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOBP_TRANSMEMBRANE_TRANSPORT, MGGAAGTG_GABP_B, GOMF_METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_MONOATOMIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY

GO Biological Process (7): zinc ion transmembrane transport (GO:0071577), zinc ion import across plasma membrane (GO:0071578), monoatomic ion transport (GO:0006811), zinc ion transport (GO:0006829), metal ion transport (GO:0030001), copper ion transmembrane transport (GO:0035434), transmembrane transport (GO:0055085)

GO Molecular Function (3): copper ion transmembrane transporter activity (GO:0005375), zinc ion transmembrane transporter activity (GO:0005385), metal ion transmembrane transporter activity (GO:0046873)

GO Cellular Component (5): nucleus (GO:0005634), cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
monoatomic cation transmembrane transport	2
zinc ion transmembrane transport	2
transport	2
transition metal ion transmembrane transporter activity	2
intracellular membrane-bounded organelle	2
cellular anatomical structure	2
zinc ion transport	1
inorganic cation import across plasma membrane	1
transition metal ion transport	1
monoatomic cation transport	1
copper ion transport	1
cellular process	1
copper ion transmembrane transport	1
monoatomic cation transmembrane transporter activity	1
metal ion transport	1
intracellular anatomical structure	1
cytoplasm	1
endomembrane system	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

780 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC39A11	SLC39A9	Q9NUM3	861
SLC39A11	SLC39A7	Q92504	838
SLC39A11	SLC39A13	Q96H72	805
SLC39A11	SLC30A7	Q8NEW0	793
SLC39A11	SLC30A9	Q6PML9	792
SLC39A11	SLC39A1	Q9NY26	789
SLC39A11	SLC39A12	Q504Y0	775
SLC39A11	SLC39A6	Q13433	768
SLC39A11	SLC39A5	Q6ZMH5	766
SLC39A11	SLC39A10	Q9ULF5	766
SLC39A11	SLC30A6	Q6NXT4	753
SLC39A11	SLC39A3	Q9BRY0	747
SLC39A11	SLC39A14	Q15043	746
SLC39A11	SLC30A1	Q9Y6M5	732
SLC39A11	SLC30A5	Q8TAD4	725

IntAct

99 interactions, top by confidence:

A	B	Type	Score
	TOMM70	psi-mi:“MI:0914”(association)	0.980
SCN2B	EXOC5	psi-mi:“MI:0914”(association)	0.640
CD33	PEX19	psi-mi:“MI:0914”(association)	0.640
FAM174A	GAK	psi-mi:“MI:0914”(association)	0.640
BTN3A2	BTN3A1	psi-mi:“MI:0914”(association)	0.600
FAM174A	BLTP3B	psi-mi:“MI:0914”(association)	0.530
PCDHB16	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
EPHA1	EXOC5	psi-mi:“MI:0914”(association)	0.530
LRRC4C	DVL2	psi-mi:“MI:0914”(association)	0.530
VASN	AP3B1	psi-mi:“MI:0914”(association)	0.530
TMEM51	WWP2	psi-mi:“MI:0914”(association)	0.530
CD274	TTI1	psi-mi:“MI:0914”(association)	0.530
SIGLEC12	HSPA5	psi-mi:“MI:0914”(association)	0.530
EFNB2	FAM171A2	psi-mi:“MI:0914”(association)	0.530
COMTD1	IFRD1	psi-mi:“MI:0914”(association)	0.530
SLC39A11	GAPDHS	psi-mi:“MI:0914”(association)	0.530
WBP1	EXTL3	psi-mi:“MI:0914”(association)	0.530
IZUMO1	ADCY3	psi-mi:“MI:0914”(association)	0.530
VAMP5	NBAS	psi-mi:“MI:0914”(association)	0.530
CD40	EXOC5	psi-mi:“MI:0914”(association)	0.530
CD274	PEX19	psi-mi:“MI:0914”(association)	0.530
GALNT16	IPO8	psi-mi:“MI:0914”(association)	0.530
NTRK3	FAM171A2	psi-mi:“MI:0914”(association)	0.480

BioGRID (227): SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS)

ESM2 similar proteins: A0A0H3LM39, A1AFW5, A1KRK6, A7ZRS2, A8ZVV7, A9MPX1, A9N5W7, B1ISB7, B1LF36, B1XG45, B2FM90, B4SPV6, B4T660, B4TI40, B4TVS2, B5BG02, B5F683, B5FV58, B5QZ27, B5REE9, B5YR85, B6I411, B7LGI2, B7LQB7, B7LZI9, B7MAB7, B7N0I9, B7ND33, B7NJQ3, B7UIV3, C0PYW1, P0A8H3, P0A8H4, P0A8H5, P67470, P67471, Q06916, Q0TD62, Q2YDD4, Q3YXK1

Diamond homologs: A0A0H3LM39, Q06916, Q28J44, Q2YDD4, Q6P6S2, Q8BWY7, Q8FTK0, Q8N1S5, Q8NQK0, Q8XMG8, Q9PIN2, A1AFW5, A1KRK6, A4SE48, A4WEI1, A7ZRS2, A8A4J6, A8ZVV7, A9MPX1, A9N5W7, B1HYT6, B1ISB7, B1LF36, B1XG45, B2FM90, B2UL32, B3ECE6, B3QP89, B4SPV6, B4T660, B4TI40, B4TVS2, B5BG02, B5F683, B5FV58, B5QZ27, B5REE9, B5YR85, B6I411, B7LGI2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 114 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
T cell costimulation	6	22.0×	3e-04
negative regulation of T cell receptor signaling pathway	5	18.0×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

72 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	3
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

4759 predictions. Top by Δscore:

Variant	Effect	Δscore
17:72647660:CCA:C	acceptor_gain	1.0000
17:72647661:CAC:C	acceptor_gain	1.0000
17:72647663:C:CC	acceptor_gain	1.0000
17:72648797:TCCAA:T	donor_loss	1.0000
17:72648798:CCAA:C	donor_loss	1.0000
17:72648799:CAA:C	donor_loss	1.0000
17:72648800:AAC:A	donor_loss	1.0000
17:72648801:A:AT	donor_loss	1.0000
17:72648802:CCT:C	donor_loss	1.0000
17:72648957:CATAC:C	acceptor_gain	1.0000
17:72648958:ATAC:A	acceptor_gain	1.0000
17:72648959:TAC:T	acceptor_gain	1.0000
17:72648960:AC:A	acceptor_gain	1.0000
17:72648960:ACC:A	acceptor_loss	1.0000
17:72648960:ACCT:A	acceptor_gain	1.0000
17:72648961:CC:C	acceptor_gain	1.0000
17:72648962:C:CA	acceptor_loss	1.0000
17:72648962:C:CC	acceptor_gain	1.0000
17:72736716:CCCT:C	acceptor_gain	1.0000
17:72736717:CCTC:C	acceptor_gain	1.0000
17:72736729:A:C	acceptor_gain	1.0000
17:72849811:A:T	acceptor_gain	1.0000
17:72947754:AT:A	donor_gain	1.0000
17:72947755:T:C	donor_gain	1.0000
17:73031548:GTACT:G	donor_loss	1.0000
17:73031550:ACTC:A	donor_loss	1.0000
17:73031552:TCAC:T	donor_loss	1.0000
17:73031553:CA:C	donor_loss	1.0000
17:73031554:A:AC	donor_gain	1.0000
17:73031554:AC:A	donor_gain	1.0000

AlphaMissense

2162 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:72648946:G:C	S269R	0.999
17:72648946:G:T	S269R	0.999
17:72648948:T:G	S269R	0.999
17:72649228:C:G	G245R	0.999
17:72649238:A:C	N241K	0.999
17:72649238:A:T	N241K	0.999
17:72736710:G:T	A211D	0.999
17:73084826:A:C	S43R	0.999
17:73084826:A:T	S43R	0.999
17:73084828:T:G	S43R	0.999
17:72647624:C:T	G330E	0.998
17:72647625:C:G	G330R	0.998
17:72647625:C:T	G330R	0.998
17:72649214:G:C	S249R	0.998
17:72649214:G:T	S249R	0.998
17:72649216:T:G	S249R	0.998
17:72649221:G:T	A247D	0.998
17:72649248:C:T	G238E	0.998
17:72649260:G:T	A234D	0.998
17:72736707:A:T	V212D	0.998
17:72736717:C:G	G209R	0.998
17:73084815:G:T	A47D	0.998
17:73088710:A:G	W19R	0.998
17:73088710:A:T	W19R	0.998
17:72647620:A:C	F331L	0.997
17:72647620:A:T	F331L	0.997
17:72647622:A:G	F331L	0.997
17:72648813:C:G	A314P	0.997
17:72648854:C:T	G300D	0.997
17:72648860:G:T	A298D	0.997

dbSNP variants (sampled 300 via entrez): RS1000001775 (17:72714124 G>A), RS1000003818 (17:73083509 G>A,C), RS1000007714 (17:72863401 A>C), RS1000012393 (17:72678778 T>C), RS1000025155 (17:72938301 C>T), RS1000025617 (17:72964830 T>C), RS1000030653 (17:72787385 G>A), RS1000037003 (17:72825589 T>C), RS1000052536 (17:73044810 G>A), RS1000053172 (17:73010754 A>C,G), RS1000057386 (17:72787184 C>T), RS1000064507 (17:72709830 T>C), RS1000068398 (17:72929506 G>A), RS1000070638 (17:72973575 T>C), RS1000072763 (17:72908785 T>C,G)

Disease associations

OMIM: gene MIM:616508 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): ependymoma (MONDO:0016698)

Orphanet (1): Ependymoma (Orphanet:251636)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST000406_6	Amyotrophic lateral sclerosis	8.000000e-06
GCST001523_31	Visceral adipose tissue adjusted for BMI	2.000000e-06
GCST001859_35	Thiazide-induced adverse metabolic effects in hypertensive patients	3.000000e-06
GCST002028_4	Serum selenium levels	4.000000e-07
GCST002183_1	Relative hand skill in reading disability	5.000000e-06
GCST002207_8	Liver enzyme levels (alanine transaminase)	6.000000e-06
GCST002396_26	Smoking initiation	1.000000e-07
GCST004131_91	Inflammatory bowel disease	4.000000e-11
GCST004133_59	Ulcerative colitis	4.000000e-10
GCST004586_2	Body mass index (ever vs never smoking interaction)	1.000000e-06
GCST004735_39	Epstein-Barr virus copy number in lymphoblastoid cell lines	3.000000e-06
GCST005537_37	Chronic inflammatory diseases (ankylosing spondylitis, Crohn’s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	6.000000e-11
GCST006658_9	Longevity	8.000000e-06
GCST006719_14	BRCA1/2-negative high-risk breast cancer	7.000000e-06
GCST007393_10	Mitochondrial DNA copy number	2.000000e-07
GCST008178_12	Early spontaneous preterm birth	3.000000e-06
GCST011742_37	Triglyceride levels in HIV infection	1.000000e-05
GCST012190_12	Body mass index and diastolic blood pressure (bivariate analysis)	4.000000e-06

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0009902	handedness
EFO:0005670	smoking initiation
EFO:0009443	BRCAX breast cancer
EFO:0006312	mitochondrial DNA measurement
EFO:0006917	spontaneous preterm birth
EFO:0004530	triglyceride measurement
EFO:0006336	diastolic blood pressure

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D004806	Ependymoma	C04.557.465.625.600.380.290; C04.557.470.670.380.290; C04.557.580.625.600.380.290

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067388 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC39 family of metal ion transporters

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.77	Kd	1698	nM	CHEMBL5653589
5.77	ED50	1707	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149423: Binding affinity to human SLC39A11 incubated for 45 mins by Kinobead based pull down assay	kd	1.6978	uM

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	6
Valproic Acid	increases expression, affects expression, affects cotreatment	6
Aflatoxin B1	increases methylation, affects expression, decreases expression	4
bisphenol A	increases methylation, affects cotreatment, increases expression	2
Calcitriol	decreases expression, increases expression, affects cotreatment	2
Tobacco Smoke Pollution	decreases expression	2
Copper Sulfate	decreases expression, increases expression	2
bisphenol F	affects cotreatment, increases expression	1
bufotalin	decreases expression	1
methyleugenol	decreases expression	1
arsenite	affects binding, increases reaction	1
sodium arsenite	increases expression	1
benzo(e)pyrene	decreases methylation	1
N-acetyl-4-benzoquinoneimine	affects response to substance	1
aflatoxin B2	decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
Grape Seed Proanthocyanidins	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases methylation	1
jinfukang	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652465	Binding	Binding affinity to human SLC39A11 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4NC	HCT116-SLC39A11-KO-c23	Cancer cell line	Male
CVCL_D4ND	HCT116-SLC39A11-KO-c5	Cancer cell line	Male
CVCL_TN52	HAP1 SLC39A11 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

95 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00517959	PHASE3	UNKNOWN	SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors
NCT01096368	PHASE3	COMPLETED	Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
NCT00003479	PHASE2	TERMINATED	Antineoplaston Therapy in Treating Patients With Ependymoma
NCT00520936	PHASE2	COMPLETED	A Study of Pemetrexed in Children With Recurrent Cancer
NCT00840047	PHASE2	ACTIVE_NOT_RECRUITING	Methionine PET/CT Studies In Patients With Cancer
NCT01088035	PHASE2	TERMINATED	Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma
NCT01247922	PHASE2	TERMINATED	Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
NCT01288235	PHASE2	COMPLETED	Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
NCT01295944	PHASE2	COMPLETED	Carboplatin and Bevacizumab for Recurrent Ependymoma
NCT01356290	PHASE2	RECRUITING	Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
NCT01836549	PHASE2	TERMINATED	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
NCT02125786	PHASE2	ACTIVE_NOT_RECRUITING	A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
NCT02689336	PHASE2	WITHDRAWN	Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
NCT03095248	PHASE2	TERMINATED	Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
NCT03155620	PHASE2	ACTIVE_NOT_RECRUITING	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03173950	PHASE2	COMPLETED	Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
NCT03194906	PHASE2	COMPLETED	Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
NCT03210714	PHASE2	ACTIVE_NOT_RECRUITING	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCT03213652	PHASE2	ACTIVE_NOT_RECRUITING	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213665	PHASE2	COMPLETED	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
NCT03213678	PHASE2	COMPLETED	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
NCT03213704	PHASE2	ACTIVE_NOT_RECRUITING	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03220035	PHASE2	COMPLETED	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
NCT03233204	PHASE2	COMPLETED	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
NCT03526250	PHASE2	COMPLETED	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
NCT03698994	PHASE2	ACTIVE_NOT_RECRUITING	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03727841	PHASE2	TERMINATED	Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
NCT04049669	PHASE2	ACTIVE_NOT_RECRUITING	Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
NCT04195555	PHASE2	ACTIVE_NOT_RECRUITING	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04284774	PHASE2	ACTIVE_NOT_RECRUITING	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888	PHASE2	ACTIVE_NOT_RECRUITING	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04374305	PHASE2	RECRUITING	Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
NCT04743661	PHASE2	ACTIVE_NOT_RECRUITING	131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
NCT06804655	PHASE2	NOT_YET_RECRUITING	Pharmacoscopy for Patients With Refractory Primary Brain Tumors
NCT07424092	PHASE2	RECRUITING	Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
NCT00634231	PHASE1	COMPLETED	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
NCT00994071	PHASE1	COMPLETED	A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
NCT01171469	PHASE1	COMPLETED	Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
NCT01331135	PHASE1	COMPLETED	Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
NCT01498783	PHASE1	COMPLETED	Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma